Introduction {#sec1}
============

The biogenic polyamines, spermine (Spm, **1**), spermidine (Spd), and their precursor putrescine (Put), are present in micromolar to millimolar concentrations in all eukaryotic cells, which a priori determines the diversity of their functions, many of which are vitally important.^[@ref1],[@ref2]^ The investigation of the individual cellular functions of Spm and Spd is complicated by the ability of polyamines to replace each other in many functions; furthermore, Spm is readily interconverted into Spd.^[@ref1]−[@ref4]^

Spd is vitally important because in addition to its many cellular functions, it is the sole donor of the aminobutyl group for the hypusination of a specific Lys residue of eukaryotic translation initiation factor 5A (eIF5A, which is an important elongation factor). This post-translational modification is crucial to allow this protein to function in protein synthesis by promoting the translation of polyproline motifs and some other ribosome-pausing sites.^[@ref5]^ Respectively, when cellular polyamine levels decrease, the hypusination of eIF5a is affected last, as demonstrated in a mutant strain of *S. cerevisiae*, which has a limited pool of Spd.^[@ref6]^ This milestone finding explains why Spd, but not Spm, plays a key role in supporting the growth of cells with chronic polyamine deficiency.

In contrast, such an exclusive function of Spm at the cellular level is not known. The deletion of the spermine synthase gene (*SMS*), or inhibition of the enzyme, exerts no dramatic effect on cell growth, but affect the cellular response to some drugs,^[@ref7]−[@ref9]^ oxidative stress, or UV irradiation.^[@ref10]^ However, Snyder-Robinson's syndrome is a very rare disease attributable to mutations in the human *SMS* gene (at chromosome Xp22.11) leading to a major decrease in the amounts of Spm and an increase in the Spd contents of tissues including the brain. The disease is characterized by intellectual disability, osteoporosis, hypotonia, speech abnormalities, and seizures.^[@ref11]^ Treatment of patient-derived lymphoblast cell lines with Spm returned their Spd/Spm-ratio within the range of wild type cells,^[@ref12]^ but as the authors discussed, a simple dietary supplementation of Spm would not be a therapeutic option. However, it is clear that Spm and consequently an appropriate Spd/Spm ratio is required for the normal physiological function of brain and other tissues.

Genetically modified microorganisms and cell lines^[@ref2],[@ref4]^ as well as transgenic animals^[@ref13]^ have been widely used to disclose the individual functions of Spm and Spd as well as the biological properties of polyamines in general. In these experiments, the use of metabolically stable, functionally active mimetics of polyamines is beneficial to avoid Spm and Spd interconversions, as first demonstrated in the case of spermidine/spermine *N*^1^-acetyltransferase (SSAT)-transgenic rats. Catabolically stable 1-methylspermidine (1-MeSpd) prevented the development of acute pancreatitis and death of the animals with induced SSAT, the rate-limiting enzyme of Spd catabolism.^[@ref14]^ Later, the investigation of the biological properties of other C-methylated Spd analogues demonstrated that all of these analogues mimicked Spd in reverting the growth inhibition caused by a 3 day treatment with the polyamine biosynthesis inhibitor α-difluoromethylornithine (DFMO) and were transported into cells via the polyamine transporter. However, the enzymes of polyamine catabolism differently recognized C-methylated Spd analogues.^[@ref15]^ Thus only 3-methylspermidine (3-MeSpd) is metabolically stable, whereas 1-methylspermidine (1-MeSpd) is not a substrate of SSAT but is converted into 1-methylspermine in DU145 cells.^[@ref15],[@ref16]^ Only 1-MeSpd and 2-methylspermidine (2-MeSpd), but not 3-MeSpd and 8-methylspermidine (8-MeSpd), support the growth of the cells after prolonged DFMO treatment, although 1-MeSpd, 2-MeSpd, and 3-MeSpd, but not 8-MeSpd, are the substrates of deoxyhypusine synthase (DHS).^[@ref17],[@ref18]^ Interestingly, among these Spd analogues, only 2-MeSpd is unable to downregulate ODC in DU145 cells.^[@ref15]^ Therefore, the biochemical properties of C-methylated Spd analogues can be adjusted by simply moving the methyl group along the polyamine backbone, and these analogues have demonstrated a good potential for studying the enzymes of polyamine metabolism and the cellular functions of Spd.^[@ref19]^

Here we have synthesized and investigated the biological properties of novel bis-methylated derivatives of Spm ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), assuming that the biochemical properties of these analogues would be determined by the position of methyl substituent(s). All of the analogues tested competed with Spm for transport into DU145 cells. The substrate properties of 1,12-Me~2~Spm (**2**), 2,11-Me~2~Spm (**3**), and 3,10-Me~2~Spm (**4**) toward SSAT, spermine oxidase (SMOX), and bovine plasma semicarbazide-sensitive amino oxidase (SSAO) depended on the position of the methyl groups. Among these compounds, **4** did not induce antizyme (OAZ1), and it was only a weak downregulator of ODC. Thus, to the best of our knowledge, **4** is the first functionally active mimetic of Spm that does not interfere with OAZ1-dependent regulatory pathways. Surprisingly, among the *C*-methylated Spd derivatives, only 2-MeSpd possesses the same set of properties,^[@ref15]^ indicating the complexity and peculiarities in the regulation of OAZ1 biosynthesis by the analogues of Spm and Spd.

![Structures of C-methylated spermine analogues and the natural polyamine Spm.](jm9b01666_0001){#fig1}

Results and Discussion {#sec2}
======================

Chemistry {#sec2.1}
---------

There are various synthetic strategies for building the backbone, that is, C--N bonds, of biogenic polyamines, their analogues, and derivatives in solution,^[@ref20],[@ref21]^ and some involve the adoption of a solid-phase technique.^[@ref22]^ The development of these synthetic methods makes it possible to obtain a wide spectrum of quite complex polyamine analogues possessing antitumor,^[@ref23]^ antiparasite,^[@ref24]^ and antibacterial^[@ref25],[@ref26]^ activities. Recently, a number of polyamine derivatives have been designed and synthesized to deliver biomolecules into cells using the polyamine transporter.^[@ref27]−[@ref29]^ These synthetic routes also proved to be suitable for the preparation of novel effective inhibitors of the cellular transport of both Spm and Spd.^[@ref30]^ On the basis of these data and our previous synthetic experience,^[@ref15],[@ref31]−[@ref33]^ convergent syntheses were used to obtain the previously unknown symmetric compounds **3** and **4** ([Schemes [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} and [2](#sch2){ref-type="scheme"}). The preparation of the novel compounds 2-MeSpm (**5**) and 2,2-Me~2~Spm (**6**) involved a stepwise elongation of the aminomethylene backbone ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

The synthesis of **3** and **4** started with commercially available 3-amino-2-methylpropanol-1 (**7**) and 4-aminobutanol-2 (**8**), which were primarily converted into *N*-Cbz-aminoalcohols **9** and **10** and then to the corresponding mesylates. Mesylates without isolation were treated with LiN~3~, and azides **11** and **12** were reduced to amines **13** and **14** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesis of the Novel Spermine Analogues **3** and **4** from Amino Alcohols\
Reagents and conditions: (a) CbzCl, H~2~O, NaHCO~3~, THF. (b) (1) MsCl, Et~3~N, C~6~H~6~, Et~2~O; (2) LiN~3~, MeOH, Δ. (c) (1) Ph~3~P, THF, Δ; (2) 40% aq H~2~NCH~3~, THF. (d) NsCl, CH~2~Cl~2~, Et~3~N. (e) (1) J(CH~2~)~4~J, DMF, K~2~CO~3~, 45 °C; (2) PhSH, DMF, K~2~CO~3~. (f) H~2~/Pd, AcOH, MeOH.](jm9b01666_0007){#sch1}

It is noteworthy that the use of 40% aq CH~3~NH~2~ to convert intermediate iminophosphoranes into amines (Staudinger reaction) proved to be superior than the traditionally used aq NH~4~OH.^[@ref34]^ Amines **13** and **14** were converted to nosylates **15** and **16**, which were alkylated with 1,4-diiodobutane in DMF in the presence of K~2~CO~3~. The alkylation was a fairly clean procedure, but for the successful isolation of **17** and **18** by column chromatography on SiO~2~, it was essential to remove any traces of unreacted nosylates **15** and **16**. For this purpose, 15--20 mol % of BnBr was added to the reaction mixture before a one-pot removal of the nosyl protecting group with PhSH. These steps consequently allowed us to obtain pure bis-Cbz-tetraamines **17** and **18** in high yield. The subsequent removal of the Cbz groups by the catalytic hydrogenation and recrystallization of tetrahydrochlorides yielded target compounds **3** and **4** in overall yields of 21 and 18% (each in eight steps), as calculated from starting materials **7** and **8**, respectively. It is noteworthy that whereas bis-Ns-Put alkylation with the corresponding *N*-Cbz-alkyl bromides is one step shorter, the use of 1,4-diiodobutane and nosylates **15** and **16** is preferable. This nosylate route provided higher yields and reduced the complexity of the reaction mixture in the stage of alkylation.

An alternative preparation of **3** and **4** started with metacrylonitrile and crotononitrile, respectively. It is more practical to perform a Michael addition of **19** and **20** to metacrylonitrile and crotononitrile, respectively ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}), than to introduce two equivalents of nitriles in the reaction with Put.

![Synthesis of Novel Spermine Analogue **3** from Dinitrile\
Reagents and conditions: (a) **21**: CH~2~=C(CH~3~)CN, 90 °C. **22**: CH~3~CH=CHCN, 90 °C. (b) Boc~2~O, THF. (c) LiAlH~4~, THF, −5 to −2 °C. (d) HCl, EtOH.](jm9b01666_0008){#sch2}

As expected, the addition of **20** to crotononitrile in the absence of a catalyst was faster than the addition of **19** to metacrylonitrile, and the reaction was virtually completed within 15 h at 90 °C (reaction was monitored by NMR). On the contrary, the reaction of **19** with metacrylonitrile required heating for 96 h to 90 °C. Compounds **21** and **22** are oily liquids (bp ca. 150 °C/0.2 Torr), and their final purification was performed using flash chromatography on SiO~2~. The reduction of bis-Boc-diaminodinitriles **23** and **24** to bis-Boc-tetraamines with LiAlH~4~ was not as straightforward as previously described^[@ref35]^ for the reduction of *N*^4^,*N*^8^-bis-(*tert*-butyloxycarbonyl)-2-methyl-8-amino-4-azaoctanenitrile and *N*^4^,*N*^8^-bis-(*tert*-butyloxycarbonyl)-3-methyl-8-amino-4-azaoctanenitrile to bis-Boc-derivatives of the corresponding C-methylated Spd's, which smoothly proceeded in Et~2~O at −5 to 0 °C. Nonetheless, it was found that neither **23** nor **24** was soluble in Et~2~O, whereas the reduction of **23** with LiAlH~4~ in THF made it possible to obtain bis-Boc-tetraamine **25** in only 15% yield because of the competing retro-Michael reaction leading to *N*^4^,*N*^8^-bis-(*tert*-butyloxycarbonyl)-2-methyl-1,8-diamino-4-azaoctane (16%) and *N*^1^,*N*^4^-bis-(*tert*-butyloxycarbonyl)-1,4-diaminobutane as the main product. The subsequent deprotection of **25** and the recrystallization of tetrahydrochloride afforded the desired **3** in an overall yield of 6.5% (four steps). The reduction of **24** with LiAlH~4~ in THF at −5 to 0 °C was unsuccessful, and the target compound *N*^4^,*N*^9^-bis-(*tert*-butyloxycarbonyl)-3,10-dimethyl-1,12-diamino-4,9-diazadodecane was not formed. Here again, the main product was *N*^1^,*N*^4^-bis-(*tert*-butyloxycarbonyl)-1,4-diaminobutane, whereas the second byproduct, *N*^4^,*N*^8^-bis-(*tert*-butyloxycarbonyl)-3-methyl-1,8-diamino-4-azaoctane, was isolated from the reaction mixture in only a 5% yield.

The reduction of **21** and **22** with H~2~/Ni-Raney gave target compounds **3** and **4** in good yield, but the products contained minor impurities, and thus the purification of preparative amounts of **3** and **4** was rather laborious. Using this synthetic scheme, we managed to obtain **3** and **4** at only 90--92% purity (data not shown). Thus the shorter "nitrile approach" in our hands was not very productive for the syntheses of **3** and **4**.

The syntheses of unsymmetric **5** and **6** were performed in five steps each ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}) by the subsequent elongation of the polyamine backbone starting with 3-\[*N*-(benzyloxycarbonyl)\]amino-1-propyl methanesulfonate (**26**), which was treated with an excess of 4-aminobutanol-1 in THF at 20 °C to produce **27**. The secondary amino group of **27** was protected with the Cbz group to give **28**, which was converted to the corresponding methanesulfonate and treated with an excess of 1,3-diamino-2-methylpropane or 1,3-diamino-2,2-dimethylpropane in THF without isolation to produce bis-Cbz-tetraamines **29** and **30** in good yield. It should be noted that the ^13^C NMR spectra of compounds **28**, **29**, and **30** (the same is true for bis-Boc-derivatives **23**, **24**, and **25**) were very complicated at 20 °C due to the existence of Cbz and Boc rotamers. Finally, the removal of Cbz groups resulted in the preparation of target compounds **5** and **6** in overall yields of 38 and 33% (each in five steps), as calculated from the starting methanesulfonate **26**.

![Synthesis of Novel Spermine Analogues **5** and **6**\
Reagents and conditions: (a) H~2~N(CH~2~)~4~OH, THF, 20 °C. (b) CbzCl, H~2~O, NaHCO~3~, THF. (c) (1) MsCl, Et~3~N, C~6~H~6~, Et~2~O; (2) **29**: H~2~NCH~2~CH(CH~3~)CH~2~NH~2~, THF, 20 °C. **30**: H~2~NCH~2~C(CH~3~)~2~CH~2~NH~2~, THF, 20 °C. (d) H~2~/Pd, AcOH, MeOH.](jm9b01666_0009){#sch3}

The above procedures allowed us to synthesize the previously unknown compounds **3**--**6** at \>95% purity and thus created the possibility to study the cellular effects of these analogues and their interactions with the enzymes of polyamine metabolism.

Biological Evaluation {#sec2.2}
---------------------

### Uptake of the Analogues and Their Effects on Intracellular Pools of Polyamines {#sec2.2.1}

The study of the biochemical potential of novel bis-methylated analogues of **1** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) was started with the investigation of their ability to be taken up by cells. All three analogues of **1** competed for uptake with \[^14^C\]-labeled **1** in DU145 prostate cancer cells. However, **3** and **4** were much weaker competitors than **2** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The competition efficacy of the analogues decreased as the methyl substituent was positioned closer to the secondary amino group, indicating that it is an important determinant in polyamine transport, a finding that is in agreement with previous observations for 3-MeSpd.^[@ref15]^

![Uptake competition of compounds **1**, **2**, **3**, and **4** (10 min) with \[^14^C\]-Spm (10 μM) in DU145 cells. Data are means ± SD, *n* = 3. \* and \*\*\* refer to the statistical significance of *p* \< 0.05 and *p* \< 0.001, respectively, as compared with the corresponding concentration of **1**.](jm9b01666_0002){#fig2}

All three analogues reduced the intracellular levels of the natural polyamines, whereas the total polyamine level (natural polyamines + analogue) remained almost unchanged ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Interestingly, after 6 h of incubation of DU145 cells with bis-methylated analogues of **1** in the absence of aminoguanidine (AG), an inhibitor of SSAO, the intracellular amount of **4** was almost half of that of **3** and about one-third of that of **2** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Apparently, after 6 h, about one half of **4** had been converted into 3-MeSpd; after 3 days of incubation, the conversion of **4** into 3-MeSpd had reached nearly 80% ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). In the presence of AG, the analogues accumulated intracellularly equally well and at levels close to that of **1** in the control samples. The transformation of **4** into 3-MeSpd was reduced but not completely prevented by AG, suggesting that **4** is catabolized not only by SSAO but also by some other enzyme. These unforeseen results prompted us to conduct comparative studies to elucidate the substrate properties of **2**, **3**, and **4** toward enzymes involved in polyamine catabolism.

###### Polyamine Pools in DU145 Cells Treated for 6 h or 3 days with 100 μM of the Analogues with or without 1 mM AG[a](#t1fn1){ref-type="table-fn"}

             Put            Spd              Spm            *N*^1^-AcSpd   analogue   MeSpd
  ---------- -------------- ---------------- -------------- -------------- ---------- ---------
  6 h                                                                                 
  control    40 ± 2         134 ± 7          106 ± 4        \<3                        
  **2**      15 ± 2\*\*\*   105 ± 10\*\*\*   84 ± 8\*\*\*   5 ± 1          70 ± 8     nd
  **3**      10 ± 1\*\*\*   99 ± 8\*\*\*     76 ± 5\*\*\*   4 ± 0          59 ± 1     nd
  **4**      27 ± 2\*\*\*   79 ± 4\*\*\*     80 ± 4\*\*\*   3 ± 0          26 ± 1     34 ± 4
  3 days                                                                              
  control    19 ± 2         123 ± 3          102 ± 4        3 ± 0                      
  **2**      \<3\*\*\*      13 ± 2\*\*\*     27 ± 3\*\*\*   \<3            168 ± 18   4 ± 1
  **3**      \<3\*\*\*      13 ± 0\*\*\*     40 ± 3\*\*\*   nd             147 ± 7    20 ± 1
  **4**      12 ± 1\*\*     34 ± 2\*\*\*     69 ± 4\*\*\*   \<3            29 ± 2     116 ± 5
  AG         16 ± 3         175 ± 5          157 ± 8        3 ± 1                      
  AG+**2**   nd             3 ± 1\*\*\*      19 ± 1\*\*\*   \<3            217 ± 6    10 ± 1
  AG+**3**   nd             \<3\*\*\*        33 ± 2\*\*\*   nd             222 ± 15   nd
  AG+**4**   nd             31 ± 2\*\*\*     68 ± 5\*\*\*   nd             191 ± 18   44 ± 3

Units are pmol/μg DNA. Data are means ± SD, *n* = 3. \*\* and \*\*\* refer to statistical significance of *p* \< 0.01 and *p* \< 0.001, respectively, as compared with the control sample. nd, not detectable.

### Interaction of Bis-Methylated Spm Analogues with the Enzymes Involved in Polyamine Catabolism {#sec2.2.2}

The study of the biochemical properties of novel bis-methylated derivatives of **1** was continued by investigating their interactions with recombinant SSAT and SMOX, which are the rate-limiting enzymes of Spm and Spd catabolism, and also with Cu^2+^-dependent bovine plasma SSAO, which is capable of utilizing both Spm and Spd as substrates. It was observed that the structure/activity relationships are unique for each enzyme and the substrate properties of bis-methylated analogues of **1** depended on the position of the methyl groups.

#### SSAT {#sec2.2.2.1}

Mouse recombinant SSAT did not acetylate **2** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A), whereas **3** and **4** were found to be approximately 7 and 12 times less preferred substrates of the enzyme than its natural substrate **1** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). The kinetic parameters for **3** were *V*~max~ = 895 ± 18 pmol/min/μg protein, *K*~m~ = 52 ± 5 μM and those for **4** were *V*~max~ = 136 ± 5 pmol/min/μg protein, *K*~m~ = 60 ± 11 μM ([Figure S1](#notes1){ref-type="notes"}). Compounds **2** and **4** were found to be poor inhibitors of the enzyme, achieving 80 and 75% inhibition at 500 μM, respectively, when the concentration of **1**, used in this assay as a substrate, was 50 μM ([Figure S2](#notes1){ref-type="notes"}). The inability of **2** to participate in the SSAT-catalyzed reaction may be attributed to the steric effect of the methyl group in the α-position of the amino group, which prevents the compound's acetylation. The poor substrate properties of **4**, having a methyl group in the γ-position of the acetylated amino group, were unexpected. However, the X-ray structure of SSAT with the binary complex, Spm-HS-CoA, clearly revealed that in the active center of the enzyme, there was no evidence of any special group being responsible for the deprotonation of the terminal amino group of **1**.^[@ref36]^ Deprotonation is achieved by a "proton wire" formed with water molecules coordinated by the substrate amino groups and the side chains of Asp93 and Glu92. This "proton wire" covers not only the N-1 amino group but also the adjacent N-4 amino group. Hence, we hypothesize that the presence of a methyl group at the third position of **4** can affect the "proton wire", and it also introduces hydrophobic contacts between **4** and the side chains of Leu128 and Trp154 (that are positioned close to the secondary (N-4) amino group), and these can restrict the N^1^-acetylation of **4**.

![Analogues as substrates for (A) mouse recombinant SSAT (5 mM analogues), (B) human recombinant SMOX (1 mM analogues), (C) human recombinant APAO (2 mM analogues), and (D) bovine plasma SSAO (5 mM analogues) in vitro. Saturating concentrations of the natural substrates were used, and the analogues were tested at the same concentrations. Data are means ± SD, *n* = 3. \*\*\* refers to statistical significance of *p* \< 0.001 as compared with Spm, respectively. nd, not detectable.](jm9b01666_0003){#fig3}

#### SMOX, APAO, and SSAO {#sec2.2.2.2}

Previously, we have demonstrated that the (*S*,*S*)-diastereomer of **2** is an approximately two-fold better substrate of SMOX than compound **1** (its natural substrate), whereas the (*R*,*R*)-diastereomer of **2** has virtually no substrate properties.^[@ref37]^ The ability of racemic **2**, **3**, and **4** to serve as substrates for SMOX decreased as the methyl substituent was positioned closer to the secondary (N-4) amino group ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). With human recombinant SMOX, the kinetic parameters for **3** were *V*~max~ = 124 ± 3 pmol/min/μg protein, *K*~m~ = 121 ± 11 μM ([Figure S1](#notes1){ref-type="notes"}); for **4**, it was not possible to determine the kinetic parameters due to its poor substrate properties. As with **1**, the analogues were poor substrates for human recombinant acetylpolyamine oxidase (APAO), an enzyme that is structurally close to SMOX but uses acetylated polyamines as substrates ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). Recently, we have synthesized N^1^-acetylated derivatives of 1-MeSpd, 2-MeSpd, 3-MeSpd, and 8-MeSpd and studied their interaction with APAO. It was observed that *N*^1^-Ac-2-MeSpd and *N*^1^-Ac-8-MeSpd, but not *N*^1^-Ac-3-MeSpd, could act as substrates of the enzyme.^[@ref38]^ Thus the structure--activity relationships for **2**, **3**, **4**, and N^1^-acetylated derivatives of 1-MeSpd, 2-MeSpd, 3-MeSpd, and 8-MeSpd were rather similar for both enzymes. This is likely because the methyl group on the third position of the polyamine backbone may restrict the proton splitting at the C-3 carbon atom and influence the formation of the Schiff base, a key intermediate of the oxidation reactions catalyzed by APAO and SMOX. The opposite dependence of the substrate properties on the position of the methyl substituent took place in the case of SSAO, where the substrate properties of **4** were already ∼30% of that of **1**. Furthermore, **4** was more efficiently degraded by bovine plasma SSAO than **3**, whereas **2** was resistant toward the enzyme ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D). It should be noted that in a recent comprehensive study, no degradation of Spd and Spm was detected in human serum under cell culture conditions but only in serum from ruminant sources.^[@ref39]^ However, a membrane-bound enzyme (VAP-1; gene name AOC3) with similar substrate specificity as bovine plasma SSAO has been identified in the human vasculature, adipocytes, chondrocytes, and odontoblasts, and a soluble form of this enzyme has also been described.^[@ref40]^

The ability of **2**, **3**, and **4** to compete in SMOX, APAO, and SSAO reactions with their natural substrates was studied using a fixed 50 μM concentration of Spm, *N*^1^-acetylspermidine (*N*^1^-Ac-Spd), and Spm, respectively. Compound **4** achieved 70% inhibition of SMOX at 50 μM, whereas **3** also displayed 70% inhibition of the enzyme, albeit at 500 μM concentration, indicating that **4** has a much lower affinity for the enzyme than compound **3** ([Figure S2](#notes1){ref-type="notes"}). In contrast, compound **3** achieved 80% inhibition of SSAO at 50 μM, whereas **2** and **4** were less effective ([Figure S2](#notes1){ref-type="notes"}). Compound **4** achieved 45% inhibition of APAO at 50 μM, whereas **2** and **3** were much less effective ([Figure S2](#notes1){ref-type="notes"}).

Taken together, our data demonstrate that the interaction and substrate and inhibitory properties of bis-methylated analogues of **1** toward the enzymes of polyamine catabolism may be regulated by a simple movement of the methyl group along the polyamine analogue backbone.

### Effects on Growth of DU145 Cells and on the Intracellular Activities of the Enzymes Involved in Polyamine Metabolism {#sec2.2.3}

Despite being substrates for SSAO (see above), **2**, **3**, and **4** did not cause marked cytotoxicity in DU145 cells, and the cells could be cultured in either the presence or absence of AG, an inhibitor of SSAO ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). In contrast, the natural polyamine **1** was very toxic in the absence of AG. All of the analogues were able to overcome the growth arrest caused by a 3 day treatment with the ODC inhibitor DFMO ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B), indicating that they are recognized as polyamine mimetics. However, it should be noted that because they are analogues of **1** and are capable of depleting intracellular natural polyamines, it is apparent that compounds **2**, **3**, and **4** do not support the growth of cells under conditions of chronic polyamine deprivations because they cannot act as precursors for hypusine synthesis.

![Growth of DU145 cells treated with 100 μM analogues for 3 days (A) with or without 1 mM AG and (B) with or without 5 mM DFMO (supplemented with 1 mM AG). Data are means ± SD, *n* = 3. \*\*\* refers to statistical significance of *p* \< 0.001 as compared with the control sample.](jm9b01666_0004){#fig4}

Compound **4** was clearly the least efficient downregulator of ODC, whereas both **3** and **2** displayed similar and much more potent downregulatory effects compared with that of **4** ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). In contrast, **3** and **4** were less potent than **2** at inhibiting AdoMetDC activity ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). The studied bis-methylated analogues of **1** elicited only minor changes in SSAT and SMOX activities in DU145 cells ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C,D).

![Activities of (A) ODC, (B) AdoMetDC, (C) SSAT, and (D) SMOX in DU145 cells treated with 100 μM of the analogues for 6 h or 3 days. Data are means ± SD, *n* = 3. \*, \*\*, and \*\*\* refer to the statistical significance of *p* \< 0.05, *p* \< 0.01, and *p* \< 0.001 as compared with the control sample, respectively.](jm9b01666_0005){#fig5}

### Antizyme-Related Effects of the Analogues {#sec2.2.4}

The described differences in the effects of bis-methylated analogues of **1** on the activity of ODC (the key and rate-limiting enzyme of polyamine biosynthesis) in DU145 cells were the most interesting and unexpected findings. Hence, we decided to study these effects in more detail, assuming them to be related to the induction of antizyme (OAZ1). The short-living OAZ1 protein is one of the key regulators of polyamine homeostasis. OAZ1 binds to the ODC subunit and directs it to the 26S proteasome, triggering a rapid decline in intracellular ODC activity. Additionally, OAZ1 is known to block the transport of extracellular polyamines into the cell and to increase polyamine efflux.^[@ref41]^ The biosynthesis of OAZ1 is induced by **1**, Spd, and their analogues. We initially investigated the ability of bis-methylated analogues of **1** to induce OAZ1 by exploiting an indirect method where we compared the uptake of the analogue in the absence and presence of cycloheximide (CHX). CHX inhibits protein synthesis, including the synthesis of short-living OAZ1. If the analogue was able to induce OAZ1,then OAZ1 would downregulate the uptake of the analogue in the absence of CHX. Interestingly, the uptakes of **1**, **2**, and **3** were each increased after the incubation of cells with CHX, unlike that of **4**, indicating that **4** might be a poor inducer of OAZ1 ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A). The results of the indirect assay were confirmed by an OAZ1 immunoblot experiment, which confirmed the lack of OAZ1 induction by compound **4** ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}C). The ability of **2**, **3**, and **4** to downregulate ODC was studied after 6 h of incubation of DU145 cells using 0.1, 10, 25, 50, and 100 μM concentrations of the analogues in the media. For comparison, the effects of **1** were studied at the same concentrations ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B). It was clear that **1**, **2**, and **3** already at 10 μM decreased the intracellular activity of ODC by as much as 80%, whereas at the same concentration, **4** decreased the ODC activity only ∼5%, and even at a 100 μM concentration it decreased the ODC activity by only 55% ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B). Thus the poor downregulatory activity of **4** cannot be associated with its lower intracellular concentration due to its partial conversion into 3-MeSpd (see the previous paragraph) because at a concentration as low as 10 μM, compounds **1**, **2**, and **3**, were able to downregulate ODC by 80%. Previously, we have studied the ability of different methylated Spd analogues to downregulate ODC activity in DU145 cells and demonstrated that only 2-MeSpd was a poor downregulator.^[@ref15]^ At the moment, it is unclear why 2-MeSpd and **4** exhibit different effects from the other methylated Spd's and bis-methylated analogues of **1**. We cannot exclude the possibility that the position of the methyl group is essential for the stabilization of the pseudoknot in the mammalian OAZ1 mRNA, located just after the termination codon of ORF1; this is known to be necessary for the +1 frameshift of OAZ1 mRNA, which is required for the biosynthesis of full-length OAZ1.^[@ref41],[@ref42]^ Whatever the reason, as far as we are aware, **4** is the first functionally active Spm mimetic that is unable to induce OAZ1. This analogue might be a useful tool for studying the regulation of the induction of OAZ1 biosynthesis by polyamines.

![(A) Analogue uptake (6 h, 100 μM) in DU145 cells in the presence and absence of the protein synthesis inhibitor CHX (10 μg/mL). Data are means ± SD, *n* = 3. \*\*\* refers to the statistical significance of *p* \< 0.001 as compared with samples without CHX. (B) ODC activity in DU145 cells treated with 0.1, 10, 25, 50, or 100 μM analogues for 6 h. (C) Induction of OAZ1 protein by the analogues (100 μM) after 4 h of treatment in the presence of MG132 (25 μM), an inhibitor of proteasomal degradation.](jm9b01666_0006){#fig6}

Conclusions {#sec3}
===========

Our data demonstrate that the electrostatic interactions of properly positioned amino groups of **2**, **3**, and **4** with cellular targets and the enzymes of polyamine metabolism are not the only mode to allow recognition of the analogue and Spm. The correct spatial organization of the key part(s) of the analogue is of crucial importance, and the recognition is affected by the presence of even a comparatively small methyl group. Moreover, by changing the position of the methyl group in the analogue backbone, it is possible to regulate the biochemical properties of bis-C-methylated analogues of Spm, making them interesting research compounds with which to study the cellular functions of the individual polyamines ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). The present results also provide new insights into the structural limitations that should be taken into consideration during the design of the drugs to treat Snyder--Robinson syndrome. Because **3** and **4** are chiral molecules, it is very likely that the different diastereomers display distinct biological properties, as has been previously demonstrated for compound **2**.^[@ref37]^

###### Summary of the Biological Properties of the Analogues and the Natural Polyamine Spm[a](#t2fn1){ref-type="table-fn"}

![](jm9b01666_0010){#gr10}

NA, not available (not measured)

Experimental Section {#sec4}
====================

General Procedures {#sec4.1}
------------------

Flash chromatography was performed on Kieselgel (40--63 μm, Merck, Germany), with eluents being indicated in the text. TLC was carried out on precoated Kieselgel 60 F~254~ plates (Merck, Germany) for the elution of (A) 4:2:1:2 *n*-BuOH/AcOH/Py/H~2~O and (B) 7:3 dioxane/25% NH~4~OH. The compounds on TLC plates were visualized after a color reaction with ninhydrin or with iodine. Proton (^1^H) and carbon (^13^C) NMR spectra were recorded on a Bruker Avance III apparatus (300.13 MHz for ^1^H; 75.43 MHz for ^13^C) using CDCl~3~ or D~2~O as solvents. Chemical shifts are given in parts per million (ppm) (δ relative residual to solvent peak for ^1^H and ^13^C when recorded in CDCl~3~ or relative to DSS when recorded in D~2~O). The letter "*J*" indicates normal ^3^*J*~HH~ couplings if not specified. Melting points (mp) were determined in open glass capillaries on a Mel-Temp 3.0 apparatus (Laboratory Devices) and are uncorrected. High-resolution mass spectra (HRMS) were measured on a Bruker micrOTOF II instrument using electrospray ionization (ESI).^[@ref43]^ The measurements were done in positive ion mode (interface capillary voltage −4500 V) with a mass range from *m*/*z* 50 to *m*/*z* 3000; external or internal calibration was done with ESI Tuning Mix (Agilent). A syringe injection was used for solutions in water for hydrochlorides **3**--**6** and acetonitrile for other compounds (flow rate 5 μL/min). Nitrogen was applied as a dry gas, and the interface temperature was set to 180 °C.

The final compounds **3**--**6** were ≥95% pure, as evidenced by NMR and analytical HPLC following the known method for polyamines and their analogues.^[@ref44]^

Materials {#sec4.2}
---------

The human prostate cancer cell line DU145 was obtained from American Type Culture Collection. Compound **2** was synthesized as previously described.^[@ref31]^ Reference compound **1** was commercially obtained with purity of ≥97% (cat. no. S3256, Sigma-Aldrich). DFMO was obtained from ILEX Oncology. Putrescine dihydrochloride (cat. no. P7505, purity ≥98%), spermidine trihydrochloride (cat. no. S2501, purity ≥98%), and aminoguanidine (cat. no. 396494, purity ≥98%) were purchased from Sigma-Aldrich. \[^14^C\]-labeled spermine tetrahydrochloride (specific activity 112 mCi/mmol), [l]{.smallcaps}-ornithine (specific activity 57 mCi/mmol), acetyl-CoA (specific activity 60 mCi/mmol), and *S*-adenosyl-[l]{.smallcaps}-methionine (specific activity 54 mCi/mmol) were obtained from GE Healthcare. All solvents were used as purchased without further purification. Methanesulfonyl chloride, benzyl chloroformate, Boc~2~O, 4-aminobutanol-1, 2,2-dimethyl-1,3-diaminopropane, thiophenol, *o*-nitrophenylsulfonyl chloride (NsCl), NaCN, triphenylphosphine, and 40% aq methylamine were purchased from Aldrich (USA). 2-Methyl-1,3-diaminopropane was supplied by TCI Europe (Belgium). Crotononitrile, metacrylonitrile, LiAlH~4~, and 4-aminobutanol-2 (**8**) were purchased from Acros (Belgium). *N*-(Benzyloxycarbonyl)-3-amino-1-propyl methanesulfonate was prepared following the published procedure.^[@ref45]^ 2-Methyl-8-amino-4-azaoctanenitrile and 3-methyl-8-amino-4-azaoctanenitrile were synthesized as previously described.^[@ref15]^ The synthesis of 2-methyl-3-aminopropanol-1 was performed starting from 3-aminoisobutyric acid (Acros, Belgium) and is described in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b01666/suppl_file/jm9b01666_si_001.pdf).

1,12-Diamino-2,11-dimethyl-4,9-diazadodecane Tetrahydrochloride (**3**) {#sec4.3}
-----------------------------------------------------------------------

### Method A {#sec4.3.1}

A suspension of Pd/black in MeOH (ca. 0.25 mL) was added to a solution of **17** (0.5 g, 1.03 mmol) in a mixture of AcOH/MeOH (1:1, 7 mL), and hydrogenation was carried out at atmospheric pressure. The solids were filtered and washed with MeOH, and the combined filtrates were evaporated to dryness in vacuo. The residue was coevaporated with EtOH (2 × 5 mL), redissolved in EtOH (4 mL), and diluted with 5 M HCl (1.0 mL), and the resulting solution was evaporated to dryness in vacuo. The residue was coevaporated with dry EtOH (3 × 5 mL) and recrystallized from a MeOH--EtOH mixture to give **3** (0.28 g, 75%) as colorless crystals: mp 241--242 °C, *R*~f~ 0.19 (A), *R*~f~ 0.14 (B). ^1^H NMR (300.13 MHz, D~2~O): δ 3.22--3.08 (m, 8H, 2\*NHC[H]{.ul}~2~CH~2~ + 1/2 H~2~NCH~2~CH(CH~3~)C[H]{.ul}~2~ + 1/2 H~2~NC[H]{.ul}~2~CH(CH~3~)CH~2~), 3.03 (dd, ^2^*J*(H,H) = 12.9 Hz, *J* = 8.6 Hz, 2H, 1/2 H~2~NCH~2~CH(CH~3~)C[H]{.ul}~2~), 2.92 (dd, ^2^*J*(H,H) = 13.1 Hz, *J* = 8.8 Hz, 2H, 1/2 H~2~NC[H]{.ul}~2~CH(CH~3~)), 2.43--2.24 (m, 2H, 2\*CH), 1.89--1.72 (m, 4H, 2\*NHCH~2~C[H]{.ul}~2~), 1.15 (d, *J* = 6.8 Hz, 6H, 2\*CH~3~). ^13^C NMR (75.43 MHz, D~2~O): δ 51.29, 48.31, 43.02, 30.06, 23.29, 14.85. HRMS: *m*/*z* calculated for C~12~H~30~N~4~ + H^+^ \[M + H^+^\]: 231.2543. Found 231.2545. HPLC analysis (2000 pmol): retention time = 26.25 min; peak area 99.9%; elution buffers and gradients were as described.^[@ref44]^

### Method B {#sec4.3.2}

To a solution of **25** (0.6 g, 1.4 mmol) in MeOH (6 mL) was added HCl/MeOH (1.5 mL, 10 M), and the mixture was stirred for 30 min at 20 °C, followed by evaporation to dryness in vacuo (bath temperature 20 °C). The residue was coevaporated with MeOH (2 × 5 mL), dissolved in a minimum volume of MeOH, and precipitated with an excess of Et~2~O, which, after drying in vacuo over P~2~O~5~/KOH, resulted in crude **3**, which was recrystallized from MeOH/EtOH to give **3** (0.4 g, 76%) as colorless crystals: mp 240--242 °C, *R*~f~ 0.21 (A), *R*~f~ 0.15 (B). ^1^H NMR (300.13 MHz, D~2~O): δ 3.21--3.08 (m, 8H, 2\*NHC[H]{.ul}~2~CH~2~ + 1/2 H~2~NCH~2~CH(CH~3~)C[H]{.ul}~2~ + 1/2 H~2~NC[H]{.ul}~2~CH(CH~3~)CH~2~), 3.02 (dd, ^2^*J*(H,H) = 12.9 Hz, *J* = 8.6 Hz, 2H, 1/2 H~2~NCH~2~CH(CH~3~)C[H]{.ul}~2~), 2.92 (dd, ^2^*J*(H,H) = 13.1 Hz, *J* = 8.8 Hz, 2H, 1/2 H~2~NC[H]{.ul}~2~CH(CH~3~)), 2.39--2.26 (m, 2H, 2\*CH), 1.87--1.70 (m, 4H, 2\*NHCH~2~C[H]{.ul}~2~), 1.15 (d, *J* = 6.8 Hz, 6H, 2\*CH~3~). ^13^C NMR (75.43 MHz, D~2~O): δ 51.26, 48.27, 42.93, 30.01, 23.27, 14.84. HRMS: *m*/*z* calculated for C~12~H~30~N~4~ + H^+^ \[M + H^+^\]: 231.2543. Found 231.2547.

1,12-Diamino-3,10-dimethyl-4,9-diazadodecane Tetrahydrochloride (**4**) {#sec4.4}
-----------------------------------------------------------------------

The compound was prepared as described for **3** from **18** (1.8 g, 3.61 mmol), which afforded **4** (1.1 g, 81%), mp 234--235 °C, *R*~f~ 0.22 (A), *R*~f~ 0.07 (B). ^1^H NMR (300.13 MHz, D~2~O): δ 3.50--3.37 (m, 2H, CH), 3.23--3.04 (m, 8H, 2\*H~2~NC[H]{.ul}~2~ + 2\*NHC[H]{.ul}~2~), 2.27--2.12 (m, 2H, C[H]{.ul}~2~CH), 2.03--1.87 (m, 2H, C[H]{.ul}~2~CH), 1.85--1.73 (m, 4H, 2\*HNCH~2~C[H]{.ul}~2~), 1.36 (d, *J* = 6.6 Hz, 6H, 2\*CH~3~). ^13^C NMR (75.43 MHz, D~2~O): δ 52.70, 44.85, 36.55, 30.88, 23.70, 15.74. HRMS: *m*/*z* calculated for C~12~H~30~N~4~ + H^+^ \[M + H^+^\]: 231.2543. Found 231.2535. HPLC analysis (2000 pmol): retention time = 26.26 min; peak area 99.8%; elution buffers and gradients were as described.^[@ref44]^

1,12-Diamino-2-methyl-4,9-diazadodecane Tetrahydrochloride (**5**) {#sec4.5}
------------------------------------------------------------------

The compound was prepared as described for **3** from **29** (1.45 g, 3 mmol). After recrystallization from MeOH/EtOH, **5** (0.89 g, 82%) was obtained as colorless crystals, mp 238--239 °C (dec.). *R*~f~ 0.21 (A), *R*~f~ 0.05 (B). ^1^H NMR (300.13 MHz, D~2~O): δ 3.22--3.06 (m, 10H, 1/2 H~2~NC[H]{.ul}~2~CH(CH~3~) + 1/2 CH(CH~3~)C[H]{.ul}~2~NH + 3\*NHC[H]{.ul}~2~CH~2~ + H~2~NC[H]{.ul}~2~CH~2~CH~2~), 3.01 (dd, ^2^*J*(H,H) = 12.9 Hz, *J* = 8.6 Hz, 1H, H~2~NCH~2~CH(CH~3~)C[H]{.ul}~2~), 2.93 (dd, ^2^*J*(H,H) = 13.1 Hz, *J* = 8.8 Hz, 1H, H~2~NC[H]{.ul}~2~CH), 2.41--2.25 (m, 1H, CH), 2.17--2.03 (m, 2H, H~2~NCH~2~C[H]{.ul}~2~), 1.87--1.73 (m, 4H, CH~2~C[H]{.ul}~2~C[H]{.ul}~2~CH~2~), 1.15 (d, 3H, CH~3~, *J* = 6.8 Hz). ^13^C NMR (75.43 MHz, D~2~O): δ 51.29, 48.32, 47.65, 45.20, 43.02, 37.22, 30.06, 24.39, 23.42, 23.27, 14.85. HRMS: *m*/*z* calculated for C~11~H~28~N~4~ + H^+^ \[M + H^+^\]: 217.2387. Found 217.2381. HPLC analysis (2000 pmol): retention time = 25.98 min; peak area 99.8%; elution buffers and gradients were as described.^[@ref44]^

1,12-Diamino-2,2-dimethyl-4,9-diazadodecane Tetrahydrochloride (**6**) {#sec4.6}
----------------------------------------------------------------------

The compound was prepared as described for **3** from **30** (1.26 g, 2.53 mmol), which, after recrystallization from MeOH/EtOH, gave **6 (**0.8 g, 84%) as colorless crystals, mp 246--247 °C. *R*~f~ 0.19 (A), *R*~f~ 0.11 (B). ^1^H NMR (300.13 MHz, D~2~O): δ 3.19--3.10 (m, 8H, H~2~NC[H]{.ul}~2~CH~2~C[H]{.ul}~2~NHC[H]{.ul}~2~ + C[H]{.ul}~2~NHCH~2~C(CH~3~)~2~), 3.09 (s, 2H, NHC[H]{.ul}~2~C(CH~3~)~2~), 3.03 (s, 2H, C(CH~3~)~2~C[H]{.ul}~2~NH~2~), 2.15--2.04 (m, 2H, H~2~NCH~2~C[H]{.ul}~2~CH~2~), 1.90--1.72 (m, 4H, NHCH~2~C[H]{.ul}~2~C[H]{.ul}~2~CH~2~), 1.17 (s, 6H, 2\*CH~3~). ^13^C NMR (75.43 MHz, D~2~O): δ 56.01, 49.16, 47.63 (2C), 45.19, 37.22, 33.25, 24.38, 23.43, 23.02, 22.20. HRMS: *m*/*z* calculated for C~12~H~30~N~4~ + H^+^ \[M + H^+^\]: 231.2543. Found 231.2539. HPLC analysis (2000 pmol): retention time = 26.28 min; peak area 100%; elution buffers and gradients were as described.^[@ref44]^

*N*-(Benzyloxycarbonyl)-3-amino-2-methylpropanol-1 (**9**) {#sec4.7}
----------------------------------------------------------

Benzyl chloroformate (9.17 g, 53.7 mmol) was added in five portions within 15 min intervals to a cooled (0 °C) and vigorously stirred mixture of 2-methyl-3-aminopropanol-1 (**7**) (4.56 g, 51.2 mmol), 2 M Na~2~CO~3~ (25 mL), 1 M NaHCO~3~ (25 mL), and THF (50 mL). Stirring was continued for 2 h at 0 °C and for 6 h at room temperature. The organic layer was separated, and the water layer was extracted with DCM (3 × 25 mL). The combined organic extracts were concentrated in vacuo. The residue was dissolved in DCM (80 mL), washed with H~2~O (20 mL), 0.5 M H~2~SO~4~ (3 × 15 mL), H~2~O (20 mL), and brine (2 × 20 mL), and dried over anhydrous MgSO~4~ and filtered. The filtrate solvent was distilled off in vacuo, and crude **9** was triturated with an ether/hexane (1:3) mixture (80 mL) and left overnight at +4 °C. The precipitate was filtered and dried in vacuo at 1 Torr to produce a white solid **9** (10.4 g, 91%). TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*-(Benzyloxycarbonyl)-4-aminobutanol-2 (**10**) {#sec4.8}
-------------------------------------------------

The compound was prepared from 4-aminobutanol-2 (**8**) (4.9 g, 55 mmol) and benzyl chloroformate (7.13 mL, 50 mmol) in a mixture of THF (55 mL), 2 M Na~2~CO~3~ (25 mL), and 1 M NaHCO~3~ (25 mL) as described for **9**. Crude **10** was triturated with an ether/hexane (1:3) mixture (60 mL) and left overnight at +4 °C. The colorless oil was separated and dried in vacuo at 1 Torr to give **10** (10.1 g, 82%). The oil solidified at +4 °C but slowly self-converted to an oil at 20 °C. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*-(Benzyloxycarbonyl)-1-amino-2-methyl-3-azidopropane (**11**) {#sec4.9}
----------------------------------------------------------------

Methanesulfonyl chloride (2.26 mL, 29 mmol) in dry DCM (15 mL) was added dropwise within 20 min to a stirred and cooled (0 °C) solution of **9** (6.33 g, 28.4 mmol) and Et~3~N (6.0 mL, 43 mmol) in dry DCM (70 mL). Stirring was continued for 1 h at 0 °C, then for 4 h at 20 °C, and the reaction mixture was poured in a 1 M NaHCO~3~ (40 mL) solution. The organic layer was separated and washed with 1 M NaHCO~3~ (2 × 30 mL), H~2~O (15 mL), 0.5 M H~2~SO~4~ (3 × 40 mL), H~2~O (15 mL), and brine (25 mL). The DCM solution was dried (MgSO~4~) and concentrated in vacuo to give intermediate *N*-(benzyloxycarbonyl)-3-amino-2-methyl-1-propyl methanesulfonate (*R*~f~ 0.55 (CHCl~3~/MeOH 97:3)), which, as such, was dissolved in MeOH (25 mL) containing LiN~3~ (2.45 g, 50 mmol) and refluxed for 1 h. The reaction mixture was concentrated in vacuo, H~2~O (20 mL) was added to the residue, and the mixture was extracted with CHCl~3~ (4 × 20 mL). Combined organic extracts were washed with H~2~O (15 mL) and brine (2 × 20 mL), dried (MgSO~4~), and evaporated to dryness in vacuo to give **11** (6.10 g, 86%, as calculated from **9**) as a viscous colorless oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*-(Benzyloxycarbonyl)-1-amino-3-azidobutane (**12**) {#sec4.10}
------------------------------------------------------

Intermediate *N*-(benzyloxycarbonyl)-4-amino-2-butyl methanesulfonate (*R*~f~ 0.37 (CHCl~3~/MeOH 98:2)), was prepared from **10** (6.9 g, 31 mmol), MsCl (2.32 mL, 30 mmol), and Et~3~N (4.85 mL, 35 mmol) as described for the synthesis of **11**. Crude methanesulfonate was refluxed with LiN~3~ (2.95 g, 60 mmol) in MeOH (40 mL) for 3 h, the reaction mixture was concentrated in vacuo, H~2~O (30 mL) was added to the residue, and the mixture was extracted with CHCl~3~ (4 × 20 mL). Combined organic extracts were washed with H~2~O (15 mL) and brine (2 × 15 mL) and dried (MgSO~4~). Crude **12** was purified on a silica gel column (120 g) using DCM as an eluent to give **12** (6.25 g, 84%) as a viscous colorless oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^1^-(Benzyloxycarbonyl)-1,3-diamino-2-methylpropane (**13**) {#sec4.11}
---------------------------------------------------------------

A solution of **11** (6.08 g, 24.5 mmol) and Ph~3~P (14.11 g, 52.7 mmol) in THF (60 mL) was refluxed for 1 h, cooled to 20 °C, added to 40% aq CH~3~NH~2~ (30 mL), and stirred at 20 °C for additional 2 h. The reaction mixture was concentrated in vacuo, the residue was poured into 1.0 M HCl (40 mL), and the solution was extracted with DCM (4 × 20 mL). The aqueous phase was diluted with 5.0 M NaOH (10 mL) and extracted with DCM (4 × 15 mL), and the extract was dried (K~2~CO~3~) and evaporated to dryness in vacuo. The residue was purified on a silica gel column (120 g) using a dioxane/25% NH~4~OH (99:1) mixture as an eluent. The appropriate fractions after concentration and drying in vacuo over P~2~O~5~ gave **13** (3.89 g, 68%) as a colorless oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^1^-(Benzyloxycarbonyl)-1,3-diaminobutane (**14**) {#sec4.12}
-----------------------------------------------------

The compound was prepared by refluxing **12** (6.2 g, 25 mmol) and Ph~3~P (13.1 g, 50 mmol) in THF (60 mL) for 1.5 h, followed by a treatment with 40% aq CH~3~NH~2~ (30 mL), as described for **13**. The isolation of **12** was performed by column chromatography on silica gel (160 g) using a dioxane/25% NH~4~OH (97:3) mixture as an eluent. The appropriate fractions were concentrated, and the residue after drying in vacuo over P~2~O~5~ afforded **14** (3.5 g, 65%) as a colorless oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^1^-(Benzyloxycarbonyl)-*N*^3^-(*o*-nitrophenylsulfonyl)-1,3-diamino-2-methylpropane (**15**) {#sec4.13}
------------------------------------------------------------------------------------------------

To the cooled (0 °C) solution of **13** (3.00 g, 13.5 mmol) and Et~3~N (2.25 mL, 16 mmol) in dry DCM (40 mL), a solution of NsCl (3.08 g, 13.9 mmol) in dry DCM (20 mL) was added within 30 min with stirring, which was continued for 1 h at 0 °C and then for 3 h at 20 °C. The reaction mixture was diluted with DCM (20 mL), the layers were separated, and the organic layer was washed with 1 M NaHCO~3~ (4 × 15 mL), H~2~O (15 mL), 10% citric acid (4 × 15 mL), H~2~O (15 mL), and brine (2 × 20 mL) and dried (MgSO~4~). The solvent was distilled off in vacuo, and the residue was dried in vacuo over P~2~O~5~ to afford **15** (5.33 g, 97%) as a colorless semisolid substance. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^1^-(Benzyloxycarbonyl)-*N*^3^-(2-nitrophenylsulfonyl)-1,3-diaminobutane (**16**) {#sec4.14}
------------------------------------------------------------------------------------

The compound was prepared as described for **15** from **14** (3.44 g, 15.5 mmol), Et~3~N (2.4 mL, 17.3 mmol), and NsCl (3.48 g, 15.7 mmol) in dry DCM that, after drying in vacuo over P~2~O~5~, gave **16** (6.14 g, 97%) as a semisolid substance. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^1^,*N*^12^-Bis(benzyloxycarbonyl)-1,12-diamino-2,11-dimethyl-4,9-diazaoctane (**17**) {#sec4.15}
-----------------------------------------------------------------------------------------

A mixture of **15** (1.76 g, 4.3 mmol), K~2~CO~3~ (1.71 g, 12.4 mmol), and 1,4-diiodobutane (0.62 g, 2 mmol) in dry DMF (10 mL) was stirred for 12 h at 40 °C, followed by the addition of BnBr (0.2 mL, 1.67 mmol) and stirring for 12 h at 20 °C. Then, K~2~CO~3~ (0.83 g, 6 mmol) and PhSH (0.85 g, 7.7 mmol) in DMF (2 mL) were added and stirring was continued for an additional 12 h at 20 °C, the salts were separated by centrifugation and washed with DMF (2 × 5 mL), and the combined supernatants were evaporated to dryness in vacuo. The residue was suspended in DCM (25 mL), washed with H~2~O (2 × 5 mL) and brine (2 × 3 mL), dried (K~2~CO~3~), concentrated in vacuo, and purified on silica gel column (60 g) using a mixture of dioxane/25% NH~4~OH (95:5) as an eluent. The appropriate fractions were concentrated, and the residue, after drying in vacuo over P~2~O~5~, afforded **17** (0.55 g, 55%) as a colorless viscous oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^1^,*N*^12^-Bis(benzyloxycarbonyl)-1,12-diamino-3,10-dimethyl-4,9-diazaoctane (**18**) {#sec4.16}
-----------------------------------------------------------------------------------------

The compound was prepared as described for **17** from **16 (**6.15 g, 15.1 mmol), K~2~CO~3~ (6.0 g, 43.5 mmol), and 1,4-diiodobutane (2.18 g, 7.03 mmol) in abs DMF. Purification on the silica gel column (160 g) using a dioxane/25% NH~4~OH (100:1 → 95:5) mixture as an eluent, concentration of the appropriate fractions, and drying the resultant residue in vacuo over P~2~O~5~ produced **18** (1.83 g, 52.3%) as a colorless viscous oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

2,11-Dimethyl-4,9-diazadodecane-1,12-dinitrile (**21**) {#sec4.17}
-------------------------------------------------------

A mixture of 2-methyl-8-amino-4-azaoctanenitrile (**19**) (11.3 g, 73 mmol) and metacrylonitrile (2.3 g, 34 mmol) was heated for 96 h at 90 °C and the reaction was monitored by NMR; then, the mixture was distilled to obtain "crude" **21** (5.8 g), bp 145--148 °C/0.2 Torr. Purification on a silica gel column (130 g) using a mixture of dioxane/25% NH~4~OH (99:1) as an eluent and the subsequent concentration of the appropriate fractions gave (after drying in vacuo over P~2~O~5~) **21** (5.0 g, 66%) as a colorless viscous oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

3,10-Dimethyl-4,9-diazadodecane-1,12-dinitrile (**22**) {#sec4.18}
-------------------------------------------------------

The compound was prepared as described for **21** from 3-methyl-8-amino-4-azaoctanenitrile (**20**) (6.56 g, 42 mmol) and crotononitrile (1.34 g, 20 mmol), except that heating was carried out at 90 °C for 15 h. The distillation of the reaction mixture gave "crude" **22** (3.7 g, bp 153--155 °C/0.17 Torr). Purification on a silica gel column (140 g) using a mixture of dioxane/25% NH~4~OH (95:5) as an eluent and concentrating the appropriate fractions gave (after drying in vacuo over P~2~O~5~) **22** (3.53 g, 79%) as a colorless viscous oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^4^,*N*^9^-Bis(*tert*-butyloxycarbonyl)-2,11-dimethyl-4,9-diazadodecane-1,12-dinitrile (**23**) {#sec4.19}
--------------------------------------------------------------------------------------------------

A solution of **21** (2.6 g, 11.7 mmol) and Boc~2~O (4.75 g, 21.8 mmol) in dioxane (25 mL) was stirred for 6 h at +20 °C and then concentrated in vacuo. The residue was dissolved in DCM (50 mL), and the solution was subsequently washed with 10% citric acid (3 × 10 mL), H~2~O (10 mL), 1 M NaHCO~3~ (10 mL), H~2~O (10 mL), and brine (2 × 10 mL) and dried (MgSO~4~). The purification of the crude material on a silica gel column (120 g) using a mixture of CHCl~3~/MeOH (100:1) as an eluent and the concentration of the appropriate fractions gave (after drying in vacuo over P~2~O~5~) **23** (4.2 g, 85%), mp 90--91 °C (EtOAc--hexane). TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^4^,*N*^9^-Bis(*tert*-butyloxycarbonyl)-3,10-dimethyl-4,9-diazadodecane-1,12-dinitrile (**24**) {#sec4.20}
--------------------------------------------------------------------------------------------------

The compound was prepared as described for **23** from **22** (3.46 g, 15.6 mmol) and Boc~2~O (6.32 g, 29 mmol) in dioxane (35 mL). The purification of the crude material on a silica gel column (130 g) using a mixture of CHCl~3~/MeOH (100:1) as an eluent and concentrating the appropriate fractions gave (after drying in vacuo over P~2~O~5~) **24** (5.34 g, 87%), mp 81.5--82 °C (EtOAc--hexane). TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^4^,*N*^9^-Bis(*tert*-butyloxycarbonyl)-1,12-diamino-2,11-dimethyl-4,9-diazadodecane (**25**) {#sec4.21}
------------------------------------------------------------------------------------------------

A solution of **23** (4.2 g, 10 mmol) in THF (15 mL) was added with mechanical stirring for 20 min to a cooled (−5 °C) suspension of LiAlH~4~ (1.63 g, 43 mmol) in THF (50 mL), and stirring was continued for 1 h at −5 to −2 °C. The reaction mixture was cooled to −10 °C and carefully subsequently quenched with H~2~O (2.3 mL), 20% aq NaOH (1.3 mL), H~2~O (6.2 mL), and 40% aq NaOH (7.5 mL), maintaining a temperature below −5 °C. After warming to 20 °C, the organic layer was separated, and the residue was treated with THF (3 × 25 mL). The combined THF extracts were concentrated in vacuo, and the residue was dissolved in DCM (50 mL), washed with brine (2 × 10 mL), and dried (K~2~CO~3~). Purification on a silica gel column (60 g) using a mixture of dioxane/25% NH~4~OH (99:1) as an eluent and the concentration of the appropriate fractions gave (after drying in vacuo over P~2~O~5~) **25** (0.65 g, 15%) as a colorless oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^1^-(Benzyloxycarbonyl)-1-amino-4-azaoctanol-8 (**27**) {#sec4.22}
----------------------------------------------------------

A solution of *N*-Cbz-3-amino-1-propyl methanesulfonate (**26**)^[@ref45]^ (5.74 g, 20 mmol) and 4-aminobutanol-1 (14.24 g, 160 mmol) in dry THF (30 mL) was stirred for 24 h at 20 °C, which was then concentrated at 0.2 Torr. A solution of 2 M NaOH (30 mL) was added to the residue, and the resulting mixture was extracted with DCM (3 × 15 mL); combined organic extracts were washed with H~2~O (2 × 10 mL) and brine (15 mL) and dried (K~2~CO~3~). Purification on a silica gel column (135 g) using a dioxane/25% NH~4~OH (95:5) mixture as an eluent and the concentration of the appropriate fractions gave (after drying in vacuo over P~2~O~5~) **27** (4.1 g, 73%) as a colorless oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^1^,*N*^4^-Bis(benzyloxycarbonyl)-1-amino-4-azaoctanol-8 (**28**) {#sec4.23}
--------------------------------------------------------------------

The compound was prepared as described for **9** from **27** (3.98 g, 14.2 mmol) and benzyl chloroformate (2.47 g, 14.5 mmol) in a mixture of THF (35 mL), 2 M Na~2~CO~3~ (20 mL), and 1 M NaHCO~3~ (55 mL), which (after drying in vacuo over P~2~O~5~) resulted in **28** (5.64 g, 96%) as a viscous oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^9^,*N*^12^-Bis(benzyloxycarbonyl)-1,12-diamino-2-methyl-4,9-diazadodecane (**29**) {#sec4.24}
--------------------------------------------------------------------------------------

Methanesulfonyl chloride (0.7 g, 6 mmol) in dry C~6~H~6~ (5 mL) was added dropwise with stirring to a cooled (+4 °C) solution of **28** (2.5 g, 6 mmol) and Et~3~N (1.1 mL, 8 mmol) in C~6~H~6~/Et~2~O (40 mL, 1:3). Stirring was continued for 1 h at +4 °C and then for 1 h at 20 °C, the precipitate was filtered, and the filtrate was subsequently washed with 1 M NaHCO~3~ (4 × 5 mL), H~2~O (5 mL), 0.5 M H~2~SO~4~ (3 × 5 mL), H~2~O (5 mL), and brine (10 mL) and dried (MgSO~4~). The solvent was evaporated in vacuo to give an intermediate *N*^1^,*N*^4^-bis(benzyloxycarbonyl)-1-amino-4-aza-8-octylmethanesulfonate (*R*~f~ 0.77 (CHCl~3~/MeOH 97:3)), which was used (without purification) to alkylate 1,3-diamino-2-methylpropane (5.3 g, 60 mmol) in THF (30 mL). The reaction mixture was kept for 16 h at 4 °C, then for 24 h at 20 °C and evaporated to dryness at 0.5 Torr. A solution of 2 M NaOH (5 mL) and DCM (15 mL) was added, the organic layer was separated, and the water phase was extracted with DCM (3 × 5 mL). The combined organic extracts were washed with H~2~O (5 mL) and brine (10 mL), dried (MgSO~4~), and filtered. The solvent was removed in vacuo, and the residue was purified on a silica gel column (65 g) using a dioxane/25% NH~4~OH (95:5) mixture as an eluent. The appropriate fractions were concentrated, and the residue after drying in vacuo over P~2~O~5~ gave **29** (1.95 g, 67%, as calculated from **28**) as a colorless oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

*N*^9^,*N*^12^-Bis(benzyloxycarbonyl)-1,12-diamino-2,2-dimethyl-4,9-diazadodecane (**30**) {#sec4.25}
------------------------------------------------------------------------------------------

The compound was prepared as described for **29** from **28** (2.9 g, 7 mmol) and 1,3-diamino-2,2-dimethylpropane (7.14 g, 70 mmol) in dry THF (50 mL) and resulted in **30** (1.95 g, 56%, as calculated from **28**) as a colorless viscous oil. TLC, NMR, and ESI-MS data are presented in the [Supporting Information](#notes1){ref-type="notes"}.

Cell Culture {#sec4.26}
------------

Cells were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich), 2 mM [l]{.smallcaps}-glutamine, and 50 μg/mL gentamycin (Sigma-Aldrich). The cells were incubated in a humidified atmosphere at +37 °C, 5% CO~2~. The cells were harvested by trypsinization, washed with phosphate-buffered saline (PBS), pelleted, and stored at −70 °C before analyses. The cell number was measured electronically with the Coulter counter model Z1 (Coulter Electronics). The cells were lysed in a buffer containing 50 mM potassium phosphate buffer pH 7.2, 0.1 mM EDTA, 0.1% Triton X-100, and 0.1 mM dithiothreitol. Samples for polyamine measurement were taken (mixed with 1/10 volumes of 50% sulphosalicylic acid with 100 μM diaminoheptane), and the rest of the lysate was centrifuged for 16 000*g* for 20 min at +4 °C. The supernatant was used for enzymatic assays of SSAT, ODC, SMOX, and AdoMetDC.

Uptake Experiments {#sec4.27}
------------------

Competition experiments inDU145 cells were done as described.^[@ref15]^ In the OAZ1-dependent uptake experiment, the cells were first incubated in the presence or absence of CHX (10 μg/mL, Sigma-Aldrich) for 1 h to prevent OAZ1 induction in response to analogues. Then, the incubation was continued with a 100 μM analog for 4 h in the presence or absence of CHX, and the intracellular concentrations of analogues were measured with HPLC.

Polyamines and Enzyme Activities {#sec4.28}
--------------------------------

Intracellular polyamines and analogues were analyzed with HPLC according to a published method.^[@ref44]^ The polyamine sample pellets were dissolved to 0.1 M NaOH, and the amount of DNA was measured using PicoGreen reagent (Invitrogen) according to the manufacturer's instructions. SSAT and ODC activities were measured as previously described,^[@ref46],[@ref47]^ respectively. AdoMetDC activity was determined as previously described,^[@ref48]^ and SMOX activity was determined as described.^[@ref16]^

Experiments with Recombinant/Purified Proteins {#sec4.29}
----------------------------------------------

Plasmid coding human SMOX was a kind gift from Dr. Carl Porter, Roswell Park Cancer Institute, NY. The recombinant protein was produced and purified as previously published.^[@ref16]^ Cloning and producing mouse recombinant SSAT have been previously described.^[@ref31]^ Experiments with purified bovine plasma SSAO (Worthington) were carried out as previously described.^[@ref49]^

Western Blot {#sec4.30}
------------

Total protein (30 μg/lane) was run on 16% SDS-PAGE, transferred to PVDF membrane (Immobilon-FL, Millipore), and probed with rabbit polyclonal anti-OAZ1 (a kind gift from Prof. Olli Jänne) and mouse monoclonal antiactin (1:1000, Santa Cruz Biotechnology) antibodies overnight. Secondary antibodies were antirabbit DyLight 649 (1:3500, Thermo Scientific) and antimouse Cy3 ECLPlex (1:15 000, GE Healthcare). The membrane was imaged using a ChemiDoc MP imager (Bio-Rad).

Statistical Analysis {#sec4.31}
--------------------

Values are means ± SD. One-way analysis of variance (ANOVA) with Tukey's post hoc test was used for multiple comparisons with the aid of a software package, GraphPad Prism 5.03 (GraphPad Software). \*, \*\*, and \*\*\* refer to *p* values of \<0.05, \<0.01, and \<0.001, respectively.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01666](https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01666?goto=supporting-info).Detailed physicochemical properties of all synthesized compounds; kinetics of the oxidation (SMOX) and acetylation (SSAT) of **3** and **4**; inhibition of SSAT, SMOX, APAO, and SSAO by **2**, **3**, and **4**; and ^1^H, ^13^C, and 2D NMR spectra of compounds **3**--**6** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b01666/suppl_file/jm9b01666_si_001.pdf))Molecular formula strings for lead compounds ([CSV](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b01666/suppl_file/jm9b01666_si_002.csv))
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AdoMetDC

:   *S*-adenosyl-[l]{.smallcaps}-methionine decarboxylase

APAO

:   acetylpolyamine oxidase

br s

:   broad signal

DMF

:   *N*,*N*-dimethylformamide

1-MeSpd

:   1-methylspermidine (1,8-diamino-5-azanonane)

2-MeSpd

:   2-methylspermidine (1,8-diamino-2-methyl-4-azanoctane)

3-MeSpd

:   3-methylspermidine (1,8-diamino-3-methyl-4-azanoctane)

1,12-Me~2~Spm

:   1,12-dimethylspermine (2,13-diamino-5,10-diazatetradecane)

2,11-Me~2~Spm

:   2,11-dimethylspermine (1,12-diamino-2,11-dimethyl-4,9-diazadodecane)

3,10-Me~2~Spm

:   3,10-dimethylspermine (1,12-diamino-3,10-dimethyl-4,9-diazadodecane)

OAZ1

:   antizyme 1

ODC

:   ornithine decarboxylase

Put

:   putrescine (1,4-diaminobutane)

Spd

:   spermidine (1,8-diamino-4-azaoctane)

Spm

:   spermine (1,12-diamino-4,9-diazadodecane)

SMOX

:   spermine oxidase

SSAO

:   semicarbazide-sensitive amine oxidase

SSAT

:   spermidine/spermine *N*^1^-acetyltransferase

THF

:   tetrahydrofuran

TLC

:   thin layer chromatography
